Watchlist 9/26/17

NOTE: ALL STOCKS IN THIS WATCHLIST ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS.

IAG: Shares Float of 463.11 Million

Technicals - Beautiful chart clearly showing a strong up trending channel since March 2017.  This will likely be bolstered with the rising tension between the US and NK. Technical indicators turning up nicely and I expect to see a stock price near $8.00 within a week.

News - Gold prices continue to move higher with growing tensions between the U.S. and North Korea and with declines in the U.S. stock market and US dollar.  This lifted the metal's appeal as a safe-haven investment.

The company also announced a significant increase in its reserves at Rosebel and higher resources at Saramacca than its initial expectations.

tuesday - IAG.png

BLRX:  Shares float of 57.45 million

Technicals - The price movement on Monday crossed the resistance line that started in late February 2017.  In addition, it looks like a cup and handle pattern is emerging nicely with a MACD cross and a RSI approaching 70.  I'm looking for a strong breakthrough of the top of the cup pattern in the next few days.

News - A number of catalysts are in play: 
1. Phase 2 of BL-8040 in combination with KEYTRUDA - COMBAT trial for Pancreatic cancer was initiated in September 2016. Partial data is due 2H 2017. Full data due 2H 2018.
2. Phase 2 trial BL-8040 Mobilization and collection of bone marrow stem cells was initiated March 2016. Partial data released March 20, 2017 with topline results by the end of 2017 with Phase 2/3 trial to be initiated 2H 2017.
3. Phase 2b BL-8040 Consolidation treatment for AML cancer patients initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.

Tuesday - blrx.png

CORT: Shares float of 102.01 million

Technicals - Indicators have reversed upwards after a brief 2 day dip.  MACD set to cross the signal line above zero as RSI crossed 70 on Monday.  Note that the price successfully topped the R1 resistance line as well as the resistance line going back to April 2017.  

News - The Motley Fool referred to CORT as one of the highest growth stocks in the market today.  Corcept Therapeutics beats Netflix in earnings growth this year and projections for next year. However, the biotech narrowly comes in second over a longer time frame, with Wall Street projecting five-year annual earnings-per-share growth of 73%.  Cushing's syndrome drug Korlym has fueled Corcept's growth. Around 20,000 Americans have Cushing's syndrome, which is caused by prolonged high levels of the hormone cortisol.  Despite shares trading at 25 times expected earnings, the strong growth prospects actually make Corcept a bargain buy.

Tuesday  - cort.png

UAN: Shares float of 66.83 million

Technicals - The price successfully bounced off the resistance line which started in February 2017.  In addition, it looks like another nice cup and handle pattern has formed which could lead to a higher stock price.  Note that RSI is approaching 70.  My PT is $4.50 by next week.

News - No significany news. 

Tuesday - uan.png

JNUG :

Technicals - Similiar to other gold-related stocks, the technical indicators for $JNUG are also reversing.  If the tensions continue to rise between the US and NK, we could see a substantial increase in the Junior Gold Miners.

News - The only news of interest is the rising tensions or war of words between Trump and NK.  

Member Login
Welcome, (First Name)!

Forgot? Show
Log In
Enter Member Area
My Profile Not a member? Sign up. Log Out